PMID- 17343551
OWN - NLM
STAT- MEDLINE
DCOM- 20070530
LR  - 20131121
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 17
IP  - 1
DP  - 2007 Feb
TI  - A pilot evaluation of the safety, tolerability, pharmacokinetics, and 
      effectiveness of memantine in pediatric patients with 
      attention-deficit/hyperactivity disorder combined type.
PG  - 19-33
AB  - BACKGROUND: Disturbances in N-methyl-D-aspartate (NMDA) receptor activity may 
      play a role in attention-deficit/hyperactivity disorder (ADHD). OBJECTIVE: This 
      study is a preliminary evaluation of the safety, pharmacokinetics, and 
      effectiveness of the NMDA receptor antagonist memantine in pediatric ADHD. 
      METHODS: An open-label, dose-finding, 8-week, trial in outpatients 6-12 years old 
      with ADHD combined type. Memantine oral solution (2 mg/mL) was titrated to 10 
      mg/day (n = 8) or 20 mg/day (n = 8). Safety data and blood samples for 
      pharmacokinetic analyses were collected. The ADHD Rating Scale-IV (ADHD-IV) and 
      Clinical Global Impression of Severity (CGI-S) scale measured the effectiveness 
      of memantine. RESULTS: There were no discontinuations due to adverse events 
      (AEs), serious AEs, deaths, or suicides. Most AEs were mild and occurred during 
      the first week of treatment. The 20 mg/day memantine dose was associated with a 
      higher rate of completion and larger mean improvement on the ADHD-IV and CGI-S 
      than 10 mg/day memantine. Pharmacokinetic analyses suggest response to memantine 
      may be dose-dependent beyond an initial threshold concentration. CONCLUSIONS: 
      This pilot study suggests that a memantine dose of 20 mg/day may be a safe and 
      possibly effective treatment for pediatric ADHD. Further investigations of 
      memantine in ADHD appear to be warranted.
FAU - Findling, Robert L
AU  - Findling RL
AD  - Department of Psychiatry, Case Western Reserve University and Division of Child & 
      Adolescent Psychiatry, University Hospitals of Cleveland, Cleveland, Ohio 
      44106-5080, USA. Robert.Findling@uhhs.com
FAU - McNamara, Nora K
AU  - McNamara NK
FAU - Stansbrey, Robert J
AU  - Stansbrey RJ
FAU - Maxhimer, Rebecca
AU  - Maxhimer R
FAU - Periclou, Antonia
AU  - Periclou A
FAU - Mann, Allison
AU  - Mann A
FAU - Graham, Stephen M
AU  - Graham SM
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Administration, Oral
MH  - Attention Deficit Disorder with Hyperactivity/blood/*drug therapy
MH  - Child
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Memantine/*administration & dosage/adverse effects/pharmacokinetics
MH  - Pilot Projects
MH  - Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors
MH  - Treatment Outcome
EDAT- 2007/03/09 09:00
MHDA- 2007/05/31 09:00
CRDT- 2007/03/09 09:00
PHST- 2007/03/09 09:00 [pubmed]
PHST- 2007/05/31 09:00 [medline]
PHST- 2007/03/09 09:00 [entrez]
AID - 10.1089/cap.2006.0044 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2007 Feb;17(1):19-33. doi: 
      10.1089/cap.2006.0044.